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Introduction: Sepsis is characterized by systemic immune activation and neutrophil-mediated endothelial barrier
integrity compromise, contributing to end-organ dysfunction. Studies evaluating endothelial barrier dysfunction induced
by neutrophils from septic patients are lacking, despite its clinical significance. We hypothesized that septic neutrophils
would cause characteristic patterns of endothelial barrier dysfunction, distinct from experimental stimulation of normal
neutrophils, and that treatment with the immunomodulatory drug β-glucan would attenuate this effect.
Methods: Blood was obtained from critically ill septic patients. Patients were either general surgery patients (Primary
Sepsis (PS)) or those with sepsis following trauma (Secondary Sepsis (SS)). Those with acute respiratory distress syndrome
(ARDS) were identified. Healthy volunteers served as controls. Neutrophils were purified and aliquots were untreated, or
treated with fMLP or β-glucan. Endothelial cells were grown to confluence and activated with tissue necrosis factor
(TNF)-α . Electric Cell-substrate Impedance Sensing (ECIS) was used to determine monolayer resistance after neutrophils
were added. Groups were analyzed by two-way analysis of variance (ANOVA).
Results: Neutrophils from all septic patients, as well as fMLP-normal neutrophils, reduced endothelial barrier
integrity to a greater extent than untreated normal neutrophils (normalized resistance of cells from septic patients
at 30 mins = 0.90 ± 0.04; at 60 mins = 0.73 ± 0.6 and at 180 mins = 0.56 ± 0.05; p < 0.05 vs normal). Compared
to untreated PS neutrophils, fMLP-treated PS neutrophils caused further loss of barrier function at all time points; no
additive effect was noted in stimulation of SS neutrophils beyond 30 min. Neutrophils from ARDS patients caused
greater loss of barrier integrity than those from non-ARDS patients, despite similarities in age, sex, septic source, and
neutrophil count. Neutrophils obtained after resolution of sepsis caused less barrier dysfunction at all time points.
β-glucan treatment of septic patients’ neutrophils attenuated barrier compromise, rendering the effect similar to that
induced by neutrophils obtained once sepsis had resolved.
Conclusions: Neutrophils from septic patients exert dramatic compromise of endothelial barrier integrity. This
pattern is mimicked by experimental activation of healthy neutrophils. The effect of septic neutrophils on the
endothelium depends upon the initial inflammatory event, correlates with organ dysfunction and resolution of
sepsis, and is ameliorated by β-glucan.Introduction
Neutrophils typify the early inflammatory response, accu-
mulating at sites of infection and tissue injury [1,2]. Endo-
thelial cells of the microvasculature represent a critical site
of barrier regulation, selectively permitting passage of fluid,
macromolecules, and cells into the extravascular tissue.* Correspondence: jonathan_reichner@brown.edu
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reproduction in any medium, provided the orThrough a complex series of interactions involving binding
of selectins, integrins, and adhesion molecules, the neutro-
phil rolls, arrests, and migrates through the endothelial
barrier [3-6]. Increased intercellular space between endo-
thelial cells permits paracellular transmigration of the neu-
trophil [3,7]. This process allows the neutrophil to follow a
chemotactic gradient to a site of infection.
In sepsis, infection elicits a systemic inflammatory re-
sponse. It has been estimated that more than 750,000
cases of severe sepsis occur in the United States each. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the pathogenesis of sepsis and have served as targets for
therapeutic trials, including cytokine mediators of the in-
flammatory response (tissue necrosis factor-α (TNFα)),
immune receptors (interleukin-1 receptor, Toll-like re-
ceptor 4), and bacterial products (endotoxin); unfortu-
nately, no target has yet been found to provide a mortality
benefit in humans [3,9-12].
Sepsis-associated mortality has been shown to increase
with the severity of sepsis [13]. In its severe form, sepsis
is accompanied by evidence of organ dysfunction, with
mortality reported to be 28 to 50% [8,14]. It is believed
that neutrophils play a critical role in the development
of organ failure. Their sequestration in capillary beds
can lead to microvascular occlusion and subsequent tis-
sue ischemia [3]. Additionally, neutrophils release a var-
iety of substances, including reactive oxygen species and
proteolytic enzymes [2,5,15], and these substances are
known to affect endothelial barrier integrity [7]. With
systemic activation of the immune system, neutrophils
accumulate in vascular beds remote from the site of in-
fection or tissue injury [10]; the widespread release of
these substances is thought to contribute to the tissue
damage associated with end-organ dysfunction such as
acute lung injury or Acute Respiratory Distress Syn-
drome (ARDS) [10,16-18].
Following initial survival from septic events, much of
the ensuing morbidity and mortality is driven by the
prolonged effects of endothelial leak and end-organ fail-
ure [19,20]. Despite the clear clinical relevance of barrier
function to morbidity and mortality in sepsis, no studies
have yet examined the effect of neutrophils obtained
from septic patients on endothelial monolayer integrity.
Models of in vitro neutrophil stimulation exist, such as
treatment with N-formyl-L-methionyl-L-leucyl-L-phenyl-
alanine (fMLP); however, models of neutrophil stimula-
tion, as well as animal models of sepsis, are unable to fully
incorporate the complex environment of the septic pa-
tient, which includes active management and resuscitation
along with comorbidities that can play a causative role in
the development of sepsis.
We sought to characterize the pattern of endothelial
barrier dysfunction induced by neutrophils from critically
ill septic patients, with the hypothesis that these neutro-
phils would affect endothelial barrier integrity differently
to both unstimulated and fMLP-stimulated neutrophils
from healthy volunteers. Furthermore, prior work from
our laboratory showed that endothelial barrier dysfunction
caused by fMLP-stimulated neutrophils obtained from
healthy donors could be ameliorated by treatment with
soluble β-glucan [21]. β-Glucan is a ligand of the leukocyte
integrin complement receptor 3 (CR3; CD11b/CD18) and
is an immunomodulatory drug that has been studied in
clinical trials as a therapeutic to reduce postoperativecomplications [22]. Whether soluble β-glucan could pro-
tect an endothelial monolayer from damage caused by
neutrophils obtained from septic donors was determined
in the current study.
Herein, we describe the novel findings that: the loss of
endothelial barrier integrity induced by fMLP stimulation
of neutrophils from healthy volunteers mimics barrier
dysfunction induced by neutrophils from septic patients;
neutrophils from patients who develop sepsis after trau-
matic injury are maximally activated with respect to their
effect upon barrier function; barrier dysfunction is exac-
erbated in the presence of neutrophils from septic pa-
tients with ARDS; resolution of sepsis is characterized by
improved barrier function; and treatment of neutrophils
with pharmaceutical-grade β-glucan attenuates the barrier-
altering effects of septic patient neutrophils, rendering their
effect upon barrier function similar to that induced by neu-
trophils obtained once sepsis has resolved.
Materials and methods
Reagents
Pharmaceutical-grade soluble β-glucan (Imprime PGG®)
was obtained from Biothera (Eagan, MN, USA). The
β-glucan preparation contained <0.02% protein, <0.01%
mannan, and 1% glucosamine. Lyophilized thrombin
from human plasma, Histopaque 1077, L-cysteine, and
dextran (~80 to 120 kDa molecular mass) were ob-
tained from Sigma Life Sciences (St Louis, MO, USA).
Rat-tail type I collagen was obtained from BD Biosciences
(Bedford, MA, USA). Recombinant human TNFα was
obtained from R&D Systems (Minneapolis, MN, USA).
Trypsin and endothelial growth medium (EGM-2), con-
taining SingleQuots® supplements, were purchased from
Lonza (Walkersville, MD, USA). Human umbilical vein
endothelial cells (HUVEC) were obtained from Cambrex
(Walkersville, MD, USA). Electric cell-substrate impedance
sensing (ECIS) cultureware electrode arrays (8W10E+)
and a 16-well array station were obtained from Applied
BioPhysics (Troy, NY, USA). All reagents used con-
tained <0.1 pg/ml endotoxin as determined by Limulus
amebocyte lysate screening (Lonza).
Patient enrollment
This study was approved by the Institutional Review
Board of Rhode Island Hospital. Written informed con-
sent to participate and report results was provided by
the patients participating in this study, or their surro-
gates. Critically ill septic patients in the surgical ICU
and the trauma ICU of our institution were prospect-
ively enrolled. Septic patients were identified as those
fulfilling two or more systemic inflammatory response
syndrome criteria with a clinically or microbiologically
confirmed source of infection. We used standard sys-
temic inflammatory response syndrome criteria, namely
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minute; temperature <36°C or >38°C; respiratory rate
>20 breaths/minute or PaCO2 <32 mmHg, or need for
mechanical ventilation; white blood cell count <4,000
cells/mm3 or >12,000 cells/mm3, or >10% bands [23].
Patients were diagnosed with sepsis based on either
microbiological data or direct inspection, such as perfo-
rated bowel at laparotomy. Pneumonia is routinely diag-
nosed at our institution using bronchoalveolar lavage,
wherein only patients with a Clinical Pulmonary Infec-
tion Score ≥6 and >100,000 colony-forming units/ml on
bronchoalveolar lavage are diagnosed with pneumonia.
Abdominal sepsis was confirmed with either micro-
biology of drained intra-abdominal abscess or Clostrid-
ium difficile, or at laparotomy wherein a perforated
viscus with purulent peritonitis was visualized. No sepsis
was diagnosed based on clinical suspicion alone. Critic-
ally ill septic patients in the surgical ICU and the trauma
ICU of our institution were prospectively enrolled within
24 hours of the diagnosis of sepsis.
Patients were categorized as either primary sepsis (PS)
or secondary sepsis (SS). PS patients were nontrauma
general surgery patients with a diagnosis of sepsis. SS pa-
tients were those who were initially admitted following
traumatic injury and subsequently developed sepsis during
the same hospitalization. Acute lung injury at the time of
participation was defined according to the American–
European Consensus Conference definition as a partial
pressure of oxygen in arterial blood:inspired oxygen frac-
tion ratio <300 mmHg, along with bilateral pulmonary
infiltrates on chest radiograph in patients without clinical
evidence of left atrial hypertension [24]. Patients were de-
termined to have resolution of sepsis when they met
fewer than two systemic inflammatory response syn-
drome criteria and had undergone treatment for their
source of sepsis, including antibiotics for pneumonia and
source control for intra-abdominal infections.
Charts were reviewed for demographics, including age
and sex. Radiographs were evaluated for evidence of pul-
monary infiltrates supporting the diagnosis of ARDS.
Laboratory data including white blood cell count, neutro-
phil count, and arterial blood gases on the day of study
participation were analyzed. In addition, charts and micro-
biological data were reviewed to identify the source of sep-
sis. Data extracted allowed for the calculation of the Acute
Physiology and Chronic Health Evaluation II score at the
time of the blood draw. Patients were excluded from
enrollment if they had received any medication known to
alter neutrophil functioning such as corticosteroids.
Neutrophil isolation
Up to 15 ml blood were collected in sterile tubes con-
taining ethylenediamine tetraacetic acid and were pro-
cessed within 30 minutes of collection without storage.Neutrophils were isolated from whole blood using gra-
dient centrifugation on Histopaque. Sedimentation of
erythrocytes was performed using 3% dextran, and the
neutrophil-rich supernatant then underwent hypotonic lysis
of residual erythrocytes, yielding a >95% pure neutrophil
population of >90% viability by trypan dye exclusion. Neu-
trophils were resuspended in Hanks Balanced Salt Solution
minus calcium and magnesium, and were counted.
To assess whether the mere presence of the neutro-
phils induced a change in endothelial barrier function or
whether the neutrophils needed to be functional, an ali-
quot of purified neutrophils underwent fixation with 1%
paraformaldehyde for 20 minutes at room temperature.
Cells were then washed twice with Hanks Balanced Salt
Solution minus calcium and magnesium, resuspended
and counted as previously described.
β-Glucan treatment
For β-glucan treatment, purified neutrophils were incu-
bated with 10 μg/ml of soluble pharmaceutical-grade
β-glucan for 20 minutes at 37°C prior to their use in bar-
rier function assays. This concentration was based on pre-
vious work by our group [21]. Dextran, a polysaccharide
of similar molecular weight to β-glucan, was used as a
negative control.
Endothelial cell culture
HUVEC were grown on gelatin-coated flasks in EGM-2
medium. Cells were incubated at 37°C with 5% CO2. Once
confluent, endothelial cells were trypsinized, counted, and
used in barrier function assays. HUVEC were used within
the first five passages.
Measurement of endothelial barrier function
ECIS technology allows determination of changes in the
impedance to current flow across an electrode in real
time [25]. Wells of sterile 8W10E+ electrode arrays were
reduced with 10 mM L-cysteine and coated with 30 μg/ml
type I collagen. Endothelial cells were then plated and
grown to confluence. Only wells with resistance of 800 to
1,800 Ohm were used in experiments. Initial experiments
were conducted in the presence and absence of 20 ng/ml
TNFα stimulation of endothelial cells for a period of 3
hours prior to the addition of neutrophils, in order to
evaluate the effect of TNFα on neutrophil-induced changes
in barrier function. All subsequent experiments, including
those evaluating patient samples, were conducted using
TNFα-activated monolayers. fMLP was added to a subset
of wells (final concentration 10–6 M) immediately prior to
addition of neutrophils. Resistance measurements were
collected at 4,000 Hz. Neutrophil viability did not diminish
through the 180-minute duration of the experiments as de-
termined by trypan blue exclusion and by Wright staining




























Figure 1 Representative electric cell-substrate impedance
sensing tracing. Change in normalized monolayer resistance with
respect to time. t = 0 represents the time of addition of thrombin,
media, untreated neutrophils from a healthy volunteer (normal),
N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP)-treated
neutrophils from the same healthy volunteer (normal/fMLP), untreated
neutrophils from a septic patient (septic), or fMLP-treated neutrophils
from the same septic patient (septic/fMLP). fMLP treatment was
undertaken using 10–6 M fMLP. All neutrophil populations were found
to cause a progressive loss of barrier function.
Fox et al. Critical Care 2013, 17:R226 Page 4 of 11
http://ccforum.com/content/17/5/R226(0.8 units/ml), a molecule known to cause immediate loss
of monolayer integrity, served as a positive control. EGM-2
medium served as a negative control. Finally, to assess
whether changes in barrier function were dependent upon
functional neutrophils, endothelial resistance was mea-
sured using paraformaldehyde fixed neutrophils. All exper-
iments were carried out at 37°C with 5% carbon dioxide.
Data analysis
Data are reported as mean normalized monolayer
resistance ± standard error of the mean. Normalization
was performed relative to the immediate pretreatment re-
sistance of the well. Statistical analysis of patient character-
istics was performed using Student’s t test for continuous
data and Fisher’s exact test for categorical data. Evaluation
of barrier function assays was performed using two-way
analysis of variance with Holm–Sidak post-hoc analysis.
Paired samples were analyzed using two-way repeated-
measures analysis of variance. Statistical significance was
defined as P <0.05.
Results
TNFα activation increases the susceptibility of endothelial
cells to loss of barrier function
Using the ECIS system, we observed changes in trans-
endothelial electrical resistance, thereby monitoring
changes in monolayer integrity. Preliminary experiments
evaluated the effect of TNFα activation of endothelial
cells. Neutrophils obtained from healthy volunteers
caused a decrease in the barrier function of HUVEC both
in the absence and the presence of TNFα activation; this
effect was greatest for activated endothelial cells (normal-
ized resistance: at 30 minutes, 0.604 ± 0.02 vs. 0.767 ±
0.07, P <0.001; and at 60 minutes, 0.565 ± 0.01 vs. 0.765 ±
0.01, P <0.001). Given that activated endothelium more
closely mimics the state of the endothelium in septic pa-
tients [26], all subsequent experiments were performed
using TNFα-activated endothelial cells.
Barrier compromise induced by neutrophils from septic
patients is mimicked by fMLP stimulation of neutrophils
from healthy volunteers
Analyses were performed evaluating the effect of neutro-
phils obtained from all critically ill septic patients (n = 18)
and neutrophils from healthy controls (n = 11); those from
healthy volunteers were either exposed to activating doses
of fMLP (10–6 M) or were left untreated. A representative
ECIS tracing is provided in Figure 1. Treatment of endo-
thelial cells with thrombin, a positive experimental control,
led to an immediate loss of monolayer integrity. Wells
containing media, which served as a negative control, did
not demonstrate significant change in resistance over time.
Endothelial barrier function was unchanged in the pres-
ence of paraformaldehyde-fixed neutrophils from bothseptic patients and healthy volunteers (data not shown),
showing that barrier function compromise depends upon
challenge with live neutrophils. All other neutrophil popu-
lations caused a progressive loss of endothelial barrier in-
tegrity. The magnitude of this effect varied with time, with
source of the cells, and with fMLP treatment.
Comparisons of the effect of neutrophils from septic
patients, normal controls and normal/fMLP neutrophils
upon endothelial barrier function are shown in Figure 2.
When compared with untreated normal neutrophils, it
was noted that neutrophils from septic patients as well as
fMLP-treated neutrophils from healthy donors induced
significantly greater loss of endothelial barrier function.
This effect was seen as early as 30 minutes after the
addition of neutrophils and persisted across all time points.
It was noted that, at all time points, there was no statisti-
cally significant difference between septic patient neutro-
phils and fMLP-treated normal neutrophils in terms of
their effect upon barrier function (normalized resistance:
at 30 minutes, 0.90 ± 0.04 vs. 0.89 ± 0.04, P = 0.37; at
60 minutes, 0.73 ± 0.06 vs. 0.75 ± 0.05, P = 0.57; and at
180 minutes, 0.56 ± 0.05 vs. 0.56 ± 0.05, P = 0.73).
Neutrophils from patients with primary sepsis, but not
secondary sepsis, can be further stimulated at all time
points
We sought to determine whether the occurrence of a
second clinical inflammatory hit (the development of
sepsis following trauma) influenced neutrophil-induced
endothelial barrier dysfunction. Septic patients were des-
ignated as either PS (n = 12) or SS (n = 6) (Table 1).
There was no difference between groups with respect to








(n = 12) (n = 6)
Age (years) 59.9 ± 7.6 44 ± 7.8 0.2
Male sex (%) 58 50 0.9
Source of sepsis (%)
Abdominal 58 67 0.9
Pneumonia 42 33 0.9
White cell count (×109 cells/l) 15.1 ± 1.1 18.1 ± 1.9 0.2
Neutrophil count (×109 cells/l) 12.2 ± 0.9 12.6 ± 1.4 0.8
Septic patients with ARDS
compared with those without
evidence of ARDS
ARDS No ARDS P value
(n = 6) (n = 12)
Age (years) 57.5 ± 8.9 54.1 ± 6.7 0.8
Male sex (%) 50 58 0.9
Source of sepsis (%)
Abdominal 67 58 0.9
Pneumonia 33 42 0.9
White cell count (×109 cells/l) 16.9 ± 2 15.7 ± 1.1 0.6
Neutrophil count (×109 cells/l) 13.5 ± 1 11.8 ± 1 0.3
Characteristics listed are those on the day of study participation. Age, white blood
cell count, and neutrophil count were analyzed using Student’s t test, and male
sex and source of sepsis were analyzed using Fisher’s exact test. There were no

























Normal (n = 11)
Normal/fMLP (n = 11)
Sepsis (n = 18)
Figure 2 Septic and normal/N-formyl-L-methionyl-L-leucyl-L-
phenylalanine neutrophils induce similar patterns of barrier
dysfunction. Change in monolayer resistance at 30 minutes, 60
minutes, and 180 minutes. Groups were analyzed using two-way
analysis of variance with Holm–Sidak post-hoc analysis. Values
presented as mean ± standard error of the mean. Both normal/
N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) and septic
patient neutrophils caused a greater change in barrier function than
untreated normal neutrophils; however, there was no difference
between normal/fMLP and septic patient neutrophils at any time
point. *P <0.05 vs. normal.
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sex (58% vs. 50%, P = 0.9) or Acute Physiology and
Chronic Health Evaluation II score (11 ± 0.9 vs. 12.4 ±
1.1, P = 0.36), and in both groups the source of sepsis
was either intra-abdominal or pneumonia, with abdominal
sepsis being the predominant source. Additional clinical
parameters are shown in Table 1. Untreated neutrophils
from PS patients caused a similar effect upon barrier func-
tion when compared with untreated neutrophils from SS
patients at all time points (normalized resistance: at 30
minutes, 0.94 ± 0.07 vs. 0.85 ± 0.03, P = 0.4; at 60 minutes,
0.75 ± 0.08 vs. 0.69 ± 0.09, P = 0.6; at 180 minutes, 0.57 ±
0.06 vs. 0.53 ± 0.08, P = 0.8). The average time to onset of
the second hit was 5 days.
fMLP was used to interrogate neutrophils from both
groups of patients, because in vitro fMLP treatment of
maximally stimulated cells would not be expected to
lead to enhanced barrier dysfunction. Following treatment
with fMLP, neutrophils from PS patients were noted to
cause a further decrease in barrier function at all time
points (normalized resistance: at 30 minutes, 0.72 ± 0.05
vs. 0.94 ± 0.07, P <0.001; at 60 minutes, 0.57 ± 0.05 vs.
0.75 ± 0.08, P <0.001; and at 180 minutes, 0.39 ± 0.04 vs.
0.57 ± 0.06, P <0.001) (Figure 3a). However, fMLP treat-
ment of SS neutrophils led to greater loss of barrier integ-
rity only at 30 minutes (normalized resistance: 0.80 ± 0.02
vs. 0.85 ± 0.03, P = 0.04); there was no difference at other
time points (normalized resistance: at 60 minutes, 0.65 ±
0.07 vs. 0.69 ± 0.09, P = 0.1; and at 180 minutes, 0.49 ±
0.07 vs. 0.53 ± 0.08, P = 0.09) (Figure 3b).
Neutrophils from septic patients with ARDS display even
greater capacity for endothelial barrier compromise
Patients meeting the definition of ARDS at the time of
study participation were identified. There was no difference
between patients with ARDS (n = 6) and those without
ARDS (n = 12) with respect to age (57.5 ± 8.9 years vs.
54.1 ± 6.7 years, P = 0.8), male sex (50% vs. 58%, P = 0.9),
abdominal source of sepsis (67% vs. 58%, P = 0.9) or Acute
Physiology and Chronic Health Evaluation II score (11.6 ±
0.99 vs. 11.0 ± 1.3, P = 0.9) Additionally, there was no dif-
ference between ARDS and non-ARDS patients in terms
of total white blood cell count (16.9 ± 2 vs. 15.7 ± 1.1,
P = 0.6) and neutrophil count (13.5 ± 1 ×109 cells/l vs.
11.8 ± 1 ×109 cells/l, P = 0.3) (Table 1). The effect of neu-
trophils obtained from septic patients with ARDS was
compared with that of neutrophils obtained from septic
patients without ARDS. At each time point, neutrophils
from ARDS patients induced significantly greater loss of
endothelial barrier integrity than those from patients with-
out ARDS (normalized resistance: at 30 minutes, 0.77 ±
0.02 vs. 0.96 ± 0.06, P = 0.045; at 60 minutes, 0.57 ± 0.04
vs. 0.81 ± 0.08, P = 0.012; and at 180 minutes, 0.43 ± 0.04
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Figure 3 N-formyl-L-methionyl-L-leucyl-L-phenylalanine treatment of primary sepsis leads to more profound loss of barrier function.
Change in monolayer resistance at 30 minutes, 60 minutes, and 180 minutes. Groups were analyzed using two-way repeated-measures analysis of
variance with Holm–Sidak post-hoc analysis. Values presented as mean ± standard error of the mean. Whereas primary sepsis (PS) neutrophils
could be further stimulated at every time point (a), this effect was only present at 30 minutes for secondary sepsis (SS) neutrophils; no difference
was noted thereafter (b). *P <0.05. fMLP, N-formyl-L-methionyl-l-leucyl-L-phenylalanine.
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in endothelial barrier function
Patients were followed over time as their septic physi-
ology resolved. All patients found to have resolution of
sepsis (n = 4) remained in the ICU at the time at which
resolution of sepsis samples were obtained. A paired
comparison of neutrophil-induced changes in barrier
integrity was then undertaken. At all time points, neutro-
phils obtained once sepsis had resolved demonstrated less
alteration of barrier function than neutrophils obtained
when the same patient was septic (normalized resistance:
at 30 minutes, 1.10 ± 0.02 vs. 0.76 ± 0.04, P = 0.048; at 60
minutes, 0.99 ± 0.05 vs. 0.62 ± 0.09, P = 0.029; and at 180
minutes, 0.82 ± 0.08 vs. 0.46 ± 0.09, P = 0.032) (Figure 5).
Treatment of neutrophils with β-glucan ameliorates loss
of barrier integrity caused by neutrophils from septic
patients
To investigate the potential therapeutic role of β-glucan,
purified neutrophils from septic patients were treated with
soluble β-glucan as described in Materials and methods.
Their effect upon barrier function was compared with that
induced by untreated neutrophils from septic patients, as
well as untreated neutrophils from resolution of sepsis pa-
tients (Figure 6). Neutrophils treated with β-glucan (n = 6)
caused less of an alteration in barrier function at all time
points compared with untreated neutrophils from septic
patients (normalized resistance: at 30 minutes, 1.07 ± 0.02
vs. 0.87 ± 0.04, P = 0.048; at 60 minutes, 0.98 ± 0.04 vs.0.72 ± 0.06, P = 0.005; and at 180 minutes, 0.77 ± 0.06 vs.
0.56 ± 0.05, P = 0.018). As a comparison, treatment of
patient neutrophils with dextran, a control polysaccharide
of similar molecular weight to β-glucan, did not improve
barrier function compared with untreated neutrophils from
septic patients (data not shown). Additionally, throughout
the course of the experiment, the effect of neutrophils
treated with β-glucan was noted to resemble the effect of
neutrophils obtained once sepsis had resolved (normalized
resistance: at 30 minutes, 1.07 ± 0.02 vs. 1.10 ± 0.02,
P = 0.8; at 60 minutes, 0.98 ± 0.04 vs. 0.99 ± 0.05, P = 0.9;
and at 180 minutes, 0.77 ± 0.06 vs. 0.82 ± 0.08, P = 0.7)
(Figure 6).
Discussion
Increased endothelial barrier permeability, and the result-
ant microvascular leak, is known to become pathologic in
the setting of sepsis. Prolonged effects of loss of endothe-
lial barrier integrity can lead to edema, hypotension, and
serious end-organ complications [15,20,27]. Therapeutic
options aimed at limiting or reversing the effects of endo-
thelial leak remain limited [28] and largely supportive.
This is the first study demonstrating the real-time
quantitative loss of barrier function induced by neutro-
phils from critically ill septic patients. We show the
kinetics to be similar to the loss of barrier integrity
due to challenge from normal neutrophils stimulated
in vitro, an effect that diminishes upon resolution of


























Figure 4 Neutrophils from acute respiratory distress syndrome patients induce greater endothelial barrier dysfunction. Change in
monolayer resistance at 30 minutes, 60 minutes, and 180 minutes. Groups were analyzed using two-way analysis of variance with Holm–Sidak
post-hoc analysis. Values presented as mean ± standard error of the mean. Neutrophils from septic patients with acute respiratory distress
syndrome (ARDS) produced greater loss of barrier function than those obtained from septic patients without ARDS. *P <0.05.
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barrier dysfunction. Moreover, the therapeutic potential of
pharmaceutical-grade β-glucan in protecting the endothe-
























Figure 5 Resolution of sepsis leads to improved barrier function. Chang
Groups were analyzed using two-way repeated-measures analysis of variance
error of the mean. The barrier-altering effect of neutrophils obtained once sep
from the same patient during sepsis. *P <0.05.Studies of neutrophils and endothelial cells in humans
have largely focused on soluble biomarkers [29,30], re-
ceptor expression [31,32], and functional assays such as
phagocytosis and reactive oxygen species production
[33]. Microvascular permeability has been found to be60 180
e (minutes)
Sepsis (n =4)
Resolution (n = 4)
e in monolayer resistance at 30 minutes, 60 minutes, and 180 minutes.
with Holm–Sidak post-hoc analysis. Values presented as mean ± standard
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Figure 6 β-Glucan attenuates loss of barrier dysfunction induced by neutrophils from septic patients. Change in monolayer resistance at
30 minutes, 60 minutes, and 180 minutes comparing neutrophil samples from all patients with sepsis (sepsis), samples obtained once sepsis had
resolved (resolution), and samples of septic patients’ neutrophils treated with β-glucan (glucan). Groups were analyzed using two-way analysis of
variance with Holm–Sidak post-hoc analysis. Values presented as mean ± standard error of the mean. Treatment of neutrophils from septic
patients with β-glucan led to an effect upon barrier function that was similar to that induced by neutrophils obtained upon resolution of sepsis;
both groups caused less barrier dysfunction than untreated neutrophils from septic patients. *P <0.05 vs. sepsis.
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compared with critically ill nonseptic patients [34]. We
show that septic patients’ neutrophils induce profound
loss of barrier function, and that, counter to our original
hypothesis, this effect is mimicked by experimental acti-
vation of normal neutrophils. Although an important but
unexpected finding, we do recognize that this is only one
aspect of neutrophil biology. As such, future work will
continue to characterize further similarities and/or differ-
ence between in vitro fMLP stimulated and septic neu-
trophils with respect to receptor alterations, intracellular
signaling pathways, and other functional aspects of these
neutrophils. This remains especially important in light of
numerous interventions that have shown promise in ani-
mal models but subsequently failed in clinical trials involv-
ing the complex physiologic environment [11,35] within
the septic patient.
Our data address a salient component of the two-hit
hypothesis [36], in which the immune system is noted to
be altered by a stimulus such as traumatic injury. Both
an exaggerated immune response and a state of immune
paralysis have been described in the post-trauma setting.
Clinical practices over the past several decades have
been altered based on this understanding with improved
patient outcomes. We wished to begin to explore a spe-
cific aspect of the immune system (neutrophils effect
upon barrier function) between patients with primary in-
fections versus the more complex inflammatory milieuof this second-hit infection. While we did not detect a
difference in the barrier dysfunction induced by neutro-
phils from patients with PS compared with those with
SS, we did reveal a marked difference in their ability to
be further activated (shown in Figure 3). Specifically, we
have demonstrated that neutrophils from patients with
PS can be further stimulated with fMLP to produce a
greater loss of endothelial barrier integrity at every time
point. This was not the case for neutrophils from patients
with SS. It is known that neutrophils obtained from trau-
matically injured patients exhibit enhanced superoxide
generation [37], as well as impaired phagocytosis and re-
duced rates of apoptosis [38], indicating that traumatic in-
jury itself can stimulate neutrophils. Superoxide generation
and proinflammatory cytokine levels are further enhanced
in those trauma patients who sustain an infectious compli-
cation [38]. Similar to our finding that neutrophils from SS
patients showed no increase in effect upon barrier function
following treatment with fMLP, Botha and colleagues have
demonstrated that neutrophils from traumatically injured
patients subjected to a second inflammatory stimulus
(platelet-activating factor) could not be further stimulated
to produce superoxide when treated with fMLP [37]. Fur-
ther work is needed to clarify whether this represents a
state of immune paralysis or maximal stimulation.
Although improved over the past decade, both sepsis and
acute lung injury continue to have mortality rates >25%
[8,14,39]. Sepsis itself is associated with pulmonary capillary
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in patients with ARDS, and correlates with mortality [41].
In a murine model of acute lung injury, reduction of endo-
thelial cell contractility was associated with reduced pul-
monary neutrophil infiltration, reduced pulmonary edema
formation, and improved survival [42]. Additionally, it is
known that neutrophils play a key role in the development
of lung injury. Using a trauma-sepsis two-hit model, Perl
and colleagues have shown that neutrophil depletion leads
to a reduction in pulmonary infiltrates and an improvement
in alveolar architecture [43]. Moreover, it has been shown
that neutrophils in bronchoalveolar lavage fluid samples
from patients with acute lung injury have elevated levels
of the integrin subunit CD11b, compared with levels on
circulating neutrophils [44]. These studies highlight the
burden of neutrophil influx and excessive endothelial per-
meability in ARDS. We have shown that clinically evident
microvascular hyperpermeability, as seen in ARDS, does
indeed correlate with endothelial barrier dysfunction
observed in vitro. Because our study evaluated only cir-
culating neutrophils from ARDS patients, we would
hypothesize that pulmonary neutrophils may demonstrate
an even greater effect.
Our data demonstrate an intriguing new finding that
clinical resolution of sepsis is paralleled by reduction in
the endothelial barrier dysfunction induced by neutro-
phils from these patients. Previous work has demon-
strated that changes in the degree of critical illness are
accompanied by functional changes of circulating neu-
trophils. Kaufmann and colleagues studied neutrophils
from patients with increasing severity of sepsis (sepsis,
severe sepsis, and septic shock) and showed that these
septic states can be distinguished on the basis of reduced
fraction of neutrophils participating in phagocytosis of
zymosan particles as well as alterations in peroxide gen-
eration [33]. Ibbotson and colleagues reported that neu-
trophils obtained from septic patients expressed high
levels of α4 integrins compared with healthy volunteers;
these levels were found to decrease as patients improved
clinically [35]. Our study highlights the novel finding of
differential effects exerted on the critically important
point of endothelial barrier dysfunction. Our data there-
fore suggest a possible therapeutic target in limiting pro-
gression of the inflammatory state associated with sepsis.
In this regard, normal healthy controls were used as a
comparison because we believe that any potential thera-
peutic interventions that may be based on these findings
will aim to restore the critically ill septic patients back to
healthy normality. At this point, choosing nonseptic crit-
ically ill patients may only address a portion of the po-
tential therapeutic opportunities.
Changes in endothelial barrier integrity have been
shown to be related to neutrophil β2 integrin signaling,
leading to changes in endothelial cytosolic free calciumand reorganization of actin filaments [1]. It has further
been suggested that altered integrin function may be an
important factor in neutrophil maldistribution remote
from sites of infection in sepsis [45]. Engagement of β2
integrins causes release of substances such as heparin-
binding protein, which is known to promote neutrophil
adhesion to endothelial cells via upregulation of adhe-
sion molecules such as intercellular adhesion molecule-1
[46], and to cause endothelial cytoskeletal reorganization
[47]. CR3 (CD11b/CD18) is one such β2 integrin, known
to participate in neutrophil adhesion and transmigration.
This molecule contains two key structural domains: the I
domain, which binds ligands such as intercellular adhesion
molecules and fibrinogen; and the lectin-like domain,
which binds microbial polysaccharides such as β-glucan.
We have previously shown that co-occupancy of these two
domains affects several neutrophil functions, leading to the
augmentation of chemotaxis [48] and attenuation of trans-
migration [21].
β-Glucan has been extensively studied as an immuno-
modulatory agent [49,50]. The soluble form of β-glucan
used here has been studied in a variety of clinical trials and
is known to be well tolerated, eliciting few side effects [51],
and is not associated with cytokine production [52]. Add-
itionally, β-glucan administration has been shown to limit
infectious complications in patients; in a randomized con-
trol trial, Dellinger and colleagues showed that periope-
rative administration of β-glucan was associated with a
significant reduction in infectious morbidity and mortality
in patients undergoing noncolorectal surgery [22].
Our laboratory has previously demonstrated that
β-glucan treatment of fMLP-treated normal neutrophils
protects endothelial barrier integrity [21]. This effect
was found to occur secondary to binding of β-glucan to
the lectin-like domain of CR3. This intervention did not
alter neutrophil adhesion to activated endothelial cells;
however, it did achieve significant retention of barrier in-
tegrity, which was paralleled by a reduction in neutrophil
transmigration. We expand upon this prior work, demon-
strating a protective effect of soluble β-glucan in neutro-
phils from septic patients. In the current study, we show
that β-glucan treatment is associated with improved bar-
rier integrity throughout the course of the experiment.
Studies using sepsis models often aim to prevent activa-
tion of neutrophils [53]; however, sepsis is rarely an event
that can be prevented. Rather, many septic events, such as
pneumonia, perforated viscus, or rapidly progressive skin
and soft tissue infections, present to clinicians in states of
advanced physiological derangement. The use of neutro-
phils from septic patients mimics the clinical state in which
such a therapeutic agent might be administered. Our data
demonstrating that β-glucan treatment can limit the ability
of septic patient neutrophils to compromise endothelial
barrier integrity, thereby causing them to behave more like
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a potential therapeutic mechanism.
Conclusions
Sepsis is marked by significant changes in neutrophil func-
tion, including the induction of endothelial barrier dysfunc-
tion. Clearly, some degree of endothelial permeability to
neutrophils is beneficial to the host, allowing for bacterial
containment and eradication; however, its prolonged and
dysregulated effects can lead to serious morbidity and mor-
tality. Endothelial barrier function represents a target with
significant diagnostic and therapeutic potential; a compre-
hensive understanding of the effect of neutrophils from
septic patients upon endothelial barrier function is critical
and will depend upon further understanding of the charac-
teristics of neutrophils obtained from septic patients, and
particularly those with organ dysfunction. Given the differ-
ences between neutrophils obtained during sepsis and dur-
ing its resolution, the phenotype of the neutrophil obtained
once sepsis has resolved may represent a therapeutic tar-
get, and β-glucan treatment may serve as a model for fu-
ture therapeutic development.
Key messages
 Neutrophils obtained from septic patients mediate
significant compromise of endothelial barrier function.
 fMLP treatment of neutrophils from healthy
individuals can mimic this effect.
 Clinically evident vascular leak seen in ARDS is
paralleled by experimentally-measurable endothelial
barrier dysfunction.
 Resolution of sepsis correlates with attenuated loss
of barrier integrity.
 β-Glucan treatment of septic patients’ neutrophils
ameliorates endothelial barrier dysfunction and may
serve as a model for development of therapeutics.
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